FDA Inspection 1298982 — Chamindra Laverty

Chamindra Laverty — FEI 3042220198

The FDA completed an inspection of Chamindra Laverty on January 14, 2026 in La Jolla, CA. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). 1 citation was issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
January 14, 2026
Fiscal Year
2026
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
La Jolla, CA (United States)

Additional Details

Clinical Investigator (CI)

Citations

IDCFRDescription
756021 CFR 312.60FD-1572, protocol compliance